The Day DeepSeek Turned Tech and Wall Street Upside Down
Wall Street has perceived the company to have an almost unbreachable defense against competition with its offerings of ...
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the ...
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...
‘Back the blue?’: Wall Street Journal drags Trump over Jan. 6 pardons
The Wall Street Journal editorial board tore into President Donald Trump for pardoning the rioters who attacked the Capitol ...
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling ...
Mayor Brandon Johnson, Gov. JB Pritzker vow to push back on President Trump as he takes oath
Mayor Brandon Johnson and Gov. JB Pritzker condemned President Trump’s agenda and character Monday just before Trump took the ...
Wall Street Lunch: AI Project Stargate A Go
Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data ...
Balanced Expectations Amid Challenges and Opportunities for Johnson & Johnson: Hold Rating Issued
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...
J&J Tops Quarterly Profit Estimates on Cancer Drug Sales
Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...
Morningstar5d
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Medical-technology and drug company's 2025 sales outlook is below consensus Johnson & Johnson's stock ... from Dow Jones Newswires and The Wall Street Journal. The potential for policy changes ...